The R&D pipeline reflects our long-term commitment to driving change to defeat obesity, haemophilia, growth disorders and other serious chronic diseases
Facts and figures specific to our Research & Development organisation
We have teamed up with the International Red Cross and Red Crescent Movement to solve the challenge of delivering care to vulnerable populations displaced by conflict.
Click through to find the answers to some of our more frequently asked questions on sustainability and responsible business practices.
We are driven by science, innovation and research and strive to share our knowledge with the global community.
Oral semaglutide shows superior reductions in HbA1c and weight compared to sitag ... Read more
Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in ... Read more
Ozempic® provided greater weight reductions for adults with a baseline BMI of or ... Read more
Tresiba® demonstrated significantly improved blood sugar control and lower rates ... Read more
Novo Nordisk A/S - Share repurchase programme ... Read more
Financial statement for the first six months of 2018,
Deutsche Bank Scandinavian Corporate Day , Helsinki
Commerzbank Sector Conference, Frankfurt
ABG Sundal Collier Large Cap Seminar , Copenhagen
Take an advanced view of the Novo Nordisk share
Click here to find further information
Link to conference call and presentation
Read about Novo Nordisk – A focused healthcare company
See relevant content for private investors
Download relevant Investor Relations material
Peter Hugreffe AnkersenHead of Investor Relations
Anders Mikkelsen Investor Relations Manager
Christina Kjær Investor Relations Manager
Valdemar Borum Svarrer Investor Relations Manager
Chilie Thomsen Investor Relations Coordinator
Sign up to receive company announcements.
Link to webcast and presentation